Actively Recruiting
Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
Led by City of Hope Medical Center · Updated on 2025-07-04
180
Participants Needed
3
Research Sites
112 weeks
Total Duration
On this page
Sponsors
C
City of Hope Medical Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This clinical trial tests how well a geriatric assessment (GA) with GA-directed treatment recommendations, compared to GA with usual care, works in identifying risk factors, reducing chemotherapy radiation toxicity and functional decline, and improving the overall quality of life in older patients with non-small cell lung cancer (NSCLC). Older patients with lung cancer undergoing chemotherapy are at an increased risk of adverse outcomes including treatment toxicity and functional and physical consequences. This makes it very challenging for the physicians to balance the benefits against the risk of chemotherapy in older cancer patients. A geriatric assessment may be useful in identifying risk factors for chemotherapy radiation toxicity. Communicating these geriatric assessment findings and assessment-based recommendations to a patient's treating physicians may help them make more informed decisions about treatment options for patients. Making treatment decisions using GA-based recommendations may reduce adverse events and improve outcomes in patients receiving treatment for NSCLC.
CONDITIONS
Official Title
Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Oncology physicians must work at the participating site with no plans to leave or retire at enrollment
- Patients with unresectable non-small cell lung cancer who are 60 years or older treated at the participating site
- Clinical staging without pathological confirmation of nodal disease is allowed
- Plan to start new cancer treatment including chemotherapy within 4-6 weeks from baseline visit
- Chemotherapy may be cytotoxic drugs, monoclonal antibodies, or targeted agents
- Eligible if receiving approved cancer treatment combined or sequential with radiation including hypofractionated radiation
- Patients with only one metastatic site and one lesion outside radiation field are eligible
- Patients may be enrolled in another treatment trial if all criteria are met
- Able to provide informed consent or have a healthcare proxy to consent
- Participant or proxy must have adequate understanding of English; inclusion of other languages depends on translator availability
You will not qualify if you...
- Planned surgery within 3 months of approach date; previous surgery is allowed
- Presence of symptomatic brain metastases if more than one at consent
- More than one metastatic site (e.g., brain and adrenal, adrenal and liver)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
City of Hope Medical Center
Duarte, California, United States, 91010
Actively Recruiting
2
University of Rochester
Rochester, New York, United States, 14642
Not Yet Recruiting
3
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here